Community Hub0 Subscribers
Community hub
Prognosis
View on Wikipediafrom Wikipedia
Prognosis (Greek: πρόγνωσις "fore-knowing, foreseeing"; pl.: prognoses) is a medical term for predicting the likelihood or expected development of a disease, including whether the signs and symptoms will improve or worsen (and how quickly) or remain stable over time; expectations of quality of life, such as the ability to carry out daily activities; the potential for complications and associated health issues; and the likelihood of survival (including life expectancy).[1][2] A prognosis is made on the basis of the normal course of the diagnosed disease, the individual's physical and mental condition, the available treatments, and additional factors.[2] A complete prognosis includes the expected duration, function, and description of the course of the disease, such as progressive decline, intermittent crisis, or sudden, unpredictable crisis.[3]
When applied to large statistical populations, prognostic estimates can be very accurate: for example the statement "45% of patients with severe septic shock will die within 28 days" can be made with some confidence, because previous research found that this proportion of patients died. This statistical information does not apply to the prognosis for each individual patient, because patient-specific factors can substantially change the expected course of the disease: additional information is needed to determine whether a patient belongs to the 45% who will die, or to the 55% who survive.[4]
Methodology
[edit]Disease and prognostic indicators
[edit]Prognostic scoring is also used for cancer outcome predictions. A Manchester score is an indicator of prognosis for small-cell lung cancer. For Non-Hodgkin lymphoma, physicians have developed the International Prognostic Index to predict patient outcome.
Other medical areas where prognostic indicators are used is in Drug-Induced Liver Injury (DILI) (Hy's law) and use of an exercise stress test as a prognostic indicator after myocardial infarction, also used to indicate multiple myeloma survival rate.[5]
End of life
[edit]Studies have found that most doctors are overly optimistic when making a prognosis; they tend to overstate how long a patient might live. For patients who are critically ill, particularly those in an intensive care unit, there are numerical prognostic scoring systems that are more accurate. The most famous of these is the APACHE II scale, which is most accurate when applied in the seven days prior to a patient's predicted death.[6]
Knowing the prognosis helps determine whether it makes more sense to attempt certain treatments or to withhold them, and thus plays an important role in end-of-life decisions and advanced care planning.[7]
Estimator
[edit]Estimators that are commonly used to describe prognoses include:
- Progression-free survival - the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse.
- Survival rate – indicating the percentage of people in a study or treatment group who are alive for a given period of time after diagnosis.
- Survival time – the remaining duration of life. If not otherwise specified, it generally starts from the time of diagnosis.
History
[edit]One of the earliest written works of medicine is the Book of Prognostics of Hippocrates, written around 400 BC. This work opens with the following statement: "It appears to me a most excellent thing for the physician to cultivate Prognosis; for by foreseeing and foretelling, in the presence of the sick, the present, the past, and the future, and explaining the omissions which patients have been guilty of, he will be the more readily believed to be acquainted with the circumstances of the sick; so that men will have confidence to intrust themselves to such a physician."[8]
For 19th-century physicians, particularly those following the French school of medicine, the main aim of medicine was not to cure disease, but rather to give a medical diagnosis and achieve a satisfying prognosis of the patient's chances.[9] Only several decades later did the focus of efforts in Western medicine shift to curing disease.[citation needed]
See also
[edit]- Cure – Substance or procedure that ends a medical condition
- Medical diagnosis – Process to identify a disease or disorder
- Nocebo – Harmful effect from negative belief
- Optimism bias – Type of cognitive bias
- Placebo (origins of technical term) – Substance or treatment of no therapeutic value
- Prediction – Statement about a future event
- Reference class forecasting – Method of predicting the future
- Relative survival – Calculation in epidemiology
- Sign (medicine) – Indications of a specific illness, including psychiatric
- Signs and symptoms – Indications of a specific illness, including psychiatric
- Survival analysis – Branch of statistics
- Survival rate – Medical analysis of disease
- Symptom – Indications of a specific illness, including psychiatric
References
[edit]- ^ "What is the prognosis of a genetic condition?". Genetics Home Reference. NIH: U.S. National Library of Medicine. Retrieved 2018-05-20.
- ^ a b "Prognosis". Nature Publishing Group. Retrieved 20 May 2018.
- ^ Hansebout, R. R.; Cornacchi, S. D.; Haines, T.; Goldsmith, C. H. (2009). "How to use an article about prognosis". Canadian Journal of Surgery. Journal Canadien de Chirurgie. 52 (4): 328–336. PMC 2724829. PMID 19680521.
- ^ Gould, Stephen Jay (2013), "The Median Isn't the Message", AMA Journal of Ethics, 15 (1): 77–81, doi:10.1001/virtualmentor.2013.15.1.mnar1-1301, PMID 23356812
- ^ "Multiple Myeloma Prognosis". Multiple Myeloma Prognosis.
- ^ Tian, Yao; Yao, Yang; Zhou, Jing; Diao, Xin; Chen, Hui; Cai, Kaixia; Ma, Xuan; Wang, Shengyu (2021). "Dynamic APACHE II Score to Predict the Outcome of Intensive Care Unit Patients". Frontiers in Medicine. 8 744907. doi:10.3389/fmed.2021.744907. ISSN 2296-858X. PMC 8826444. PMID 35155461.
- ^ Kim, Peter; Daly, Jeanette M.; Berry-Stoelzle, Maresi A.; Schmidt, Megan E.; Michaels, LeAnn C.; Dorr, David A.; Levy, Barcey T. (March 2020). "Prognostic Indices for Advance Care Planning in Primary Care: A Scoping Review". The Journal of the American Board of Family Medicine. 33 (2): 322–338. doi:10.3122/jabfm.2020.02.190173. ISSN 1557-2625. PMC 7772823. PMID 32179616.
- ^ "The Internet Classics Archive – The Book of Prognostics by Hippocrates". classics.mit.edu. Retrieved 19 March 2018.
- ^ "Diagnosis: Understanding illness | Science Museum".
External links
[edit]
Look up prognosis in Wiktionary, the free dictionary.
Prognosis
View on Grokipediafrom Grokipedia
Definition and Fundamentals
Core Definition
In medicine, prognosis refers to the predicted course, duration, and likely outcome of a disease, injury, or health condition, based on current medical knowledge and evidence.[2] It provides an informed estimate of how the condition may progress, including the potential for recovery, remission, or deterioration, and is essential for guiding treatment decisions and patient counseling.[4] The term originates from the Greek prognōsis, meaning "foreknowledge," derived from pro- ("before") and gignōskein ("to know"), underscoring its role in anticipating future health trajectories through clinical foresight.[5] Unlike a diagnosis, which identifies and confirms the presence of a specific disease or condition through examination and testing, prognosis focuses on future expectations rather than current identification.[6] It also differs from a general forecast or prediction, as it is grounded in medical specificity, incorporating factors like disease stage and response to therapy, rather than broad speculation.[7] Prognoses are often categorized by time frame or outlook; for instance, a short-term prognosis might assess recovery within weeks or months, while a long-term one evaluates outcomes over years.[2] Favorable prognoses suggest a high likelihood of positive resolution, such as full recovery, whereas unfavorable ones indicate risks of progression or complications.[4] These assessments typically rely on established prognostic indicators to inform accuracy.[4]Historical Context in Medicine
The concept of prognosis emerged as a fundamental aspect of medical practice in ancient Greece through the Hippocratic Corpus, a collection of approximately 60-70 medical texts compiled around 400 BCE and attributed to Hippocrates of Cos and his followers. These works elevated prognosis to one of the core arts of medicine, alongside diagnosis and treatment, emphasizing the physician's role in predicting disease outcomes based on careful observation of symptoms, patient history, and environmental influences rather than supernatural causes. Prognostication was deemed more valuable than therapy in some contexts, as it allowed physicians to advise on the likely course of illness and prepare patients accordingly; for instance, the text Prognostic details signs like facial color, breathing, and sputum to forecast recovery or death. The Aphorisms, another key component, offer concise prognostic rules, such as the observation that laborious sleep signals a deadly symptom, while restorative sleep indicates improvement.[8][9] In the medieval era, Islamic scholars preserved and expanded Greek medical traditions, prominently integrating prognosis with humoral theory in systematic treatises. Avicenna (Ibn Sina), a Persian polymath, synthesized these ideas in his Canon of Medicine (completed in 1025 CE), a comprehensive encyclopedia that became the standard medical reference in Europe and the Islamic world for centuries. The work's first book outlines the four humors—blood, phlegm, yellow bile, and black bile—as central to health, with prognosis involving the assessment of humoral imbalances to predict disease progression and outcomes; for example, excess black bile was linked to melancholy and poor prognosis if untreated. Avicenna stressed empirical signs alongside humoral analysis for accurate forecasting, influencing prognostic practices by providing structured methods to evaluate temperament, pulse, urine, and symptoms, thereby bridging ancient observation with more organized medieval scholarship.[10][11] The Renaissance (14th-17th centuries) marked a pivotal shift toward empirical methods in medicine, with anatomists like Andreas Vesalius and William Harvey prioritizing direct observation over astrological or purely theoretical predictions. Vesalius' De Humani Corporis Fabrica (1543) relied on human dissections to correct Galenic errors, enabling more precise understandings of anatomy that informed prognostic judgments on surgical risks and disease effects. Harvey's Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus (1628) demonstrated blood circulation through vivisections and experiments, replacing humoral speculations with mechanistic explanations that improved predictions of cardiovascular outcomes. This emphasis on verifiable evidence gradually diminished reliance on astrology-influenced prognostication prevalent in medieval texts. By the 18th century, Enlightenment figures furthered this transition, advocating probabilistic and observational approaches; for instance, British clinicians like George Fordyce promoted critical evaluation of evidence in An Attempt to Improve the Evidence of Medicine (1783), fostering evidence-based prognostic reasoning that laid foundations for modern clinical practice.[12][13]Methodological Foundations
Prognostic Indicators
Prognostic indicators encompass a range of biological, clinical, and pathological markers that inform the anticipated course and outcome of diseases, particularly in oncology and chronic conditions. These indicators are essential for stratifying patients into risk groups and guiding therapeutic decisions, drawing from established categories that include clinical observations, laboratory measurements, imaging findings, and histopathological assessments. By evaluating these markers, clinicians can estimate survival probabilities and disease progression, though their interpretation requires context-specific validation from large-scale studies. Clinical prognostic indicators primarily involve observable symptoms and vital signs that reflect a patient's overall functional status and physiological stability. For instance, the Eastern Cooperative Oncology Group (ECOG) performance status scale evaluates a patient's ability to perform daily activities, with higher scores (indicating greater impairment) strongly correlating with reduced progression-free survival and overall survival in advanced cancer cohorts.[14] Vital signs, such as elevated respiratory rates or hypotension, also serve as early harbingers of deterioration in acutely ill patients, predicting higher mortality risks in conditions like sepsis or palliative care settings.[15] Symptoms like unexplained weight loss or fatigue further contribute to prognostic models by signaling systemic disease burden, as evidenced in multicenter evaluations of hospitalized patients.[16] Laboratory-based indicators focus on quantifiable biomarkers in blood or other fluids that signal disease activity or response to therapy. Prostate-specific antigen (PSA) levels exemplify this category in prostate cancer, where elevated or rising PSA post-treatment predicts recurrence and poorer long-term outcomes independent of other factors.[17] Similarly, elevated lactate dehydrogenase (LDH) levels in non-Hodgkin lymphoma patients indicate increased tumor burden and aggressive disease, associating with reduced response to chemotherapy and shorter survival durations across histological subtypes.[18] These biomarkers are routinely integrated into risk stratification, with thresholds derived from prospective cohort analyses showing their independent prognostic value when adjusted for stage and comorbidities.[19] Imaging indicators utilize radiological techniques to visualize structural changes, such as tumor dimensions assessed via magnetic resonance imaging (MRI), which provide non-invasive prognostic insights. In cervical cancer, MRI-measured tumor size greater than 4 cm correlates with diminished disease-specific survival and higher recurrence rates, outperforming clinical palpation in accuracy.[20] These metrics help delineate local invasion and response to neoadjuvant therapy, informing adjustments in treatment intensity based on volumetric reductions observed in follow-up scans.[21] Histopathological indicators derive from tissue analysis and are pivotal for detailed disease classification. The tumor-node-metastasis (TNM) staging system, developed by the American Joint Committee on Cancer, categorizes malignancies by primary tumor extent (T), regional lymph node involvement (N), and distant metastasis (M), directly linking higher stages to worse prognosis across solid tumors like lung and breast cancer.[22] For example, in small cell lung cancer, TNM stages effectively delineate survival differences in real-world cohorts, with stage IV patients exhibiting median survival under 12 months compared to over 24 months for stage I.[23] Pathological grading within TNM further refines predictions by incorporating cellular differentiation and mitotic activity.[24] In multifactorial prognostic assessment, these indicators are weighted and combined based on evidence from longitudinal cohort studies, where relative contributions are quantified through multivariate analyses to enhance predictive accuracy beyond single markers. For instance, tumor-related factors like TNM stage often carry greater weight than host-related clinical signs in oncology models, as demonstrated in comprehensive reviews of prognostic factor integration. This approach allows for personalized risk profiles, such as in older adults where combining ECOG status with laboratory biomarkers improves mortality forecasts over univariate assessments.[25] Despite their utility, prognostic indicators exhibit limitations, including substantial variability in their predictive strength across disease types and populations, necessitating disease-specific validation to avoid overgeneralization. Moreover, isolated use often underperforms compared to integrated models, as single indicators like LDH may overlook confounding influences, underscoring the need for multimodal data fusion in clinical practice.[26] Overinterpretation of these markers without rigorous cohort-derived evidence can also lead to biased decision-making, highlighting ongoing challenges in standardization.[27]Statistical and Modeling Techniques
Statistical and modeling techniques form the quantitative backbone of prognostic assessment in medicine, enabling the derivation of survival probabilities and risk estimates from clinical data. These methods process prognostic indicators—such as patient demographics, biomarkers, and disease characteristics—into predictive models that account for time-to-event outcomes, often handling censored data where the event of interest (e.g., death or recurrence) is not observed for all subjects. Central to these approaches is survival analysis, which focuses on the time until an adverse event occurs, providing tools to estimate and compare survival distributions across patient groups.[28] A foundational concept in survival analysis is the survival function, which quantifies the probability that an individual survives beyond a given time $ t $. Mathematically, it is expressed as
where $ \lambda(u) $ represents the hazard function, or the instantaneous rate of the event occurring at time $ u $ given survival up to that point. This non-increasing function decreases from 1 to 0 as $ t $ increases, reflecting the cumulative risk over time; the integral in the exponent captures the cumulative hazard $ H(t) = \int_0^t \lambda(u) , du $, allowing for flexible modeling of varying risks.[29]
For non-parametric estimation of the survival function from observed data, the Kaplan-Meier estimator is widely used, particularly for time-to-event data with censoring. It constructs a step function by multiplying conditional survival probabilities at each observed event time, providing an intuitive visualization via Kaplan-Meier curves that compare survival across cohorts without assuming an underlying distribution. Introduced in 1958, this method remains a staple for initial exploratory analysis in prognostic studies due to its simplicity and robustness.[30]
To incorporate covariates and quantify their impact on survival, semi-parametric models like the Cox proportional hazards model extend these techniques. The model assumes that the effects of predictors are multiplicative on the hazard scale, formulated as
where $ h_0(t) $ is the baseline hazard function (unspecified), $ X $ are the covariates, and $ \beta $ are the regression coefficients yielding hazard ratios $ \exp(\beta_j) $ that indicate relative risk changes per unit increase in $ X_j $. Developed in 1972, the Cox model has revolutionized prognostic modeling by enabling risk stratification while avoiding parametric assumptions about the baseline hazard, with applications spanning oncology and cardiology.[31]
Prognostic indices aggregate multiple indicators into composite scores or visual tools for clinical risk assessment. Scoring systems, such as the Acute Physiology and Chronic Health Evaluation II (APACHE II), assign points to physiological variables, age, and comorbidities to predict hospital mortality in intensive care patients, with scores ranging from 0 to 71 correlating to rising risk probabilities. Nomograms, graphical representations of regression models, allow users to plot covariate values along axes to derive personalized survival estimates, often outperforming traditional staging in cancer prognosis by integrating continuous variables.[32][33]
Advancements in machine learning have introduced data-driven approaches to handle high-dimensional and nonlinear relationships in prognostic datasets, surpassing traditional models in predictive accuracy for complex scenarios. Random forests, ensemble methods combining multiple decision trees, excel at feature selection and reducing overfitting, yielding robust survival predictions by averaging hazard estimates across trees. Neural networks, particularly deep learning variants, capture intricate interactions through layered architectures, enabling end-to-end learning from electronic health records for tasks like recurrence risk in oncology, though they require large datasets to mitigate interpretability challenges. Recent reviews highlight their integration with survival analysis, such as random survival forests, achieving superior calibration in multicenter studies.[34][35]
Prognostic Tools and Estimation
Types of Prognostic Estimators
Prognostic estimators encompass a range of tools used to quantify the probability of disease progression, complications, or mortality, often integrating clinical, laboratory, and demographic data. These estimators are broadly classified into risk scores, staging systems, and predictive models, each tailored to particular diseases or patient populations to facilitate clinical decision-making.[36] Risk scores are simplified algorithms that aggregate multiple risk factors into a single numerical value to estimate short- or long-term outcomes. A prominent example is the Framingham Risk Score, developed to predict the 10-year risk of coronary heart disease events such as myocardial infarction or coronary death in adults without prior cardiovascular disease. It incorporates variables like age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, smoking status, and diabetes, assigning points to each to yield a total score that corresponds to risk categories ranging from low (<10%) to high (>30%). This score has been widely adopted in primary care for guiding preventive interventions.[36] Staging systems provide a structured classification of disease extent, correlating anatomical spread with expected survival and treatment response. The American Joint Committee on Cancer (AJCC) TNM staging system is a cornerstone for oncology, evaluating tumors based on size (T), lymph node involvement (N), and metastasis (M) to assign stages from 0 (in situ) to IV (advanced). For instance, in breast cancer, stage I indicates a small tumor without nodal spread, associated with >90% 5-year survival, while stage IV signifies distant metastasis with poorer prognosis. The AJCC system, updated periodically, integrates these elements to standardize prognosis across cancer types and inform therapeutic strategies.[37] Predictive models employ mathematical formulas derived from statistical analyses to forecast outcomes using laboratory and clinical parameters. The Model for End-Stage Liver Disease (MELD) score exemplifies this approach for assessing mortality risk in patients with advanced liver disease awaiting transplantation. The formula is:
where values are capped (e.g., creatinine at 4 mg/dL) to avoid extremes; higher scores (>30) indicate greater 3-month mortality risk, up to 70% or more. Developed from survival data in cirrhotic patients, MELD prioritizes organ allocation based on urgency.[38]
Disease-specific estimators further refine predictions for targeted conditions, such as community-acquired pneumonia. The CURB-65 score, a validated tool for assessing severity and 30-day mortality, assigns one point each for confusion, urea >7 mmol/L, respiratory rate ≥30/min, blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), and age ≥65 years; scores of 0-1 suggest low risk (<3% mortality, suitable for outpatient management), while ≥3 indicates high risk (>17% mortality, warranting hospitalization). This simple bedside tool integrates readily available indicators to guide antibiotic and admission decisions.
Digital tools enhance accessibility and personalization of these estimators through software applications. PredictMD.jl, an open-source Julia package, enables the development and deployment of machine learning-based predictive models for clinical outcomes, automating workflows from data preprocessing to model validation. It supports integration of diverse datasets, such as electronic health records, to generate individualized prognosis estimates, for example, in predicting postoperative complications. Such platforms facilitate real-time calculations and scenario testing in clinical settings.[39]
These estimators often integrate prognostic indicators—such as biomarkers or vital signs—with underlying statistical techniques like logistic regression or survival analysis to produce reliable forecasts. For instance, risk scores like Framingham combine additive point systems derived from Cox proportional hazards models, while predictive models like MELD use continuous variables in logarithmic transformations for precision. This synthesis allows clinicians to layer multiple data sources, improving the granularity of prognosis without requiring advanced computational expertise.[38][36]
Validation and Accuracy Assessment
Validation of prognostic tools involves rigorous testing to ensure their reliability and applicability in clinical settings. Internal validation techniques, such as k-fold cross-validation, assess model performance by partitioning the development dataset into subsets, training the model on k-1 subsets, and testing on the remaining subset, repeating this process k times to estimate generalizability and reduce bias from single splits.[40] Discrimination, the ability to distinguish between individuals who experience the event and those who do not, is commonly evaluated using receiver operating characteristic (ROC) curves, where the area under the curve (AUC) quantifies overall performance, with values closer to 1 indicating better discrimination.[41] Calibration, which measures the agreement between predicted probabilities and observed outcomes, is visualized through calibration plots that compare predicted risks against observed event rates, ideally forming a straight line at 45 degrees for perfect calibration; deviations highlight systematic over- or under-prediction.[42] Key performance metrics include sensitivity (true positive rate) and specificity (true negative rate), which evaluate the model's ability to correctly identify event occurrences and non-occurrences, respectively, often balanced via ROC analysis to optimize thresholds for clinical use.[41] For survival models, the concordance index (C-index), also known as Harrell's C, serves as a primary measure of discrimination, defined as the proportion of all possible patient pairs where the predicted survival times align with the observed order:
Here, concordant pairs are those where the patient with the higher predicted risk has a shorter observed survival time, accounting for censoring; a C-index of 0.5 indicates random prediction, while values approaching 1 demonstrate strong predictive ordering.
Despite these methods, challenges persist in prognostic model validation. Overfitting occurs when models perform well on training data but poorly on new data due to excessive complexity, often mitigated through regularization or validation techniques, yet it remains a common issue in high-dimensional datasets.[43] External validation, testing models on independent datasets from different populations, is essential for confirming generalizability but is frequently underutilized; for instance, systematic reviews of cancer recurrence models reveal that many nomograms exhibit diminished accuracy outside their development cohorts, with C-indices dropping by 0.05-0.10 in external tests due to variations in patient demographics or treatment practices.[44] Studies on ovarian cancer nomograms have similarly shown moderate external performance, underscoring the need for multi-center validation to address these limitations.[45]
Regulatory frameworks have evolved to address validation for AI-based prognostic tools, particularly post-2020. The U.S. Food and Drug Administration (FDA) emphasizes robust clinical validation in its 2021 AI/ML-Based Software as a Medical Device (SaMD) Action Plan, requiring premarket submissions to include performance metrics like sensitivity, specificity, and calibration, alongside external validation to demonstrate safety and effectiveness across diverse populations. Updated guidelines, including the 2024 finalized Predetermined Change Control Plans, mandate lifecycle management for adaptive AI models, ensuring ongoing re-validation as algorithms evolve to maintain accuracy in prognostic applications such as risk stratification for chronic diseases.